Autopsy report · NCT04575558

HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19

“Withdrawn due to lack of study centers interested in participating.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Latin American Cooperative Oncology Group

Sponsor type

University, hospital or other

Conditions

Sars-CoV2

Interventions

Hydroxychloroquine and Azithromycin

Participants

0

Sites

7

Countries

Brazil

Trials that died the same way

• Characteristic Analysis and Surgical Exploration for Acetabular Roof Fractures: Multicenter Retrospective Cohort Study
  “Due to limited funding, the study is now being withdrawn.” (81% match in meaning)
• Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
  “Study was withdrawn due to lack of patient enrollment.” (80% match in meaning)
• Sym004 Versus TAS-102 in Patients With mCRC
  “Study was withdrawn due to administrative reasons” (80% match in meaning)
• A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia
  “Study is being withdrawn for business reasons” (80% match in meaning)
• Ozurdex Monotherapy Trial
  “The study was withdrawn due to insufficient participant enrollment.” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.